Messenger RNA-Based Vaccines Against Infectious Diseases
Messenger RNA-Based Vaccines Against Infectious Diseases
复制标题
DOI：
10.1007/82_2020_202
复制
发表时间：
2022-01-01
期刊：
影响因子：
--
通讯作者：
Pardi, Norbert
中科院分区：
文献类型：
--
作者：
Alameh, Mohamad-Gabriel;Weissman, Drew;Pardi, Norbert
体外转录的基于信使RNA的传染病疫苗有可能成功解决传统疫苗平台的许多弱点，例如缺乏疫苗保护的效力和/或持久性，耗时和昂贵的制造，以及在某些情况下的安全性问题。这种乐观情绪受到最近大量令人印象深刻的数据的推动，这些数据表明mRNA疫苗具有许多人类使用的可行的新疫苗类别所必需的属性。本文简要介绍了mRNA疫苗的类型，讨论了最相关的和最近的出版物上的传染病mRNA疫苗，并强调了需要克服的障碍，使这种有前途的新的疫苗模式的临床。
In vitro-transcribed, messenger RNA-based infectious disease vaccines have the potential to successfully address many of the weaknesses of traditional vaccine platforms, such as the lack of potency and/or durability of vaccine protection, time-consuming, and expensive manufacturing, and, in some cases, safety issues. This optimism is fueled by a great deal of impressive recent data demonstrating that mRNA vaccines have many of the attributes that are necessary for a viable new vaccine class for human use. This review briefly describes mRNA vaccine types, discusses the most relevant and recent publications on infectious disease mRNA vaccines, and highlights the hurdles that need to be overcome to bring this promising novel vaccine modality to the clinic.